PDCD1 and cancer: The development of T cell immune-checkpoint inhibitors (ICI) such as antibodies blocking the programmed cell death protein 1 (PD1) or its ligand (PD-L1) and the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), has rapidly introduced immunotherapy for clinical management of several cancer types.9